Protagenic Therapeutics Inc New (PTIX) Return on Assets ROA from the second quarter of 2026 to second quarter of 2026 and for the year 2026, Average High and Low, Fundamental Ratios from Sep 30 2026 to Sep 30 2025 - CSIMarket
CSIMarket
 


Protagenic Therapeutics Inc new  (NASDAQ: PTIX)


Protagenic Therapeutics Inc New's ROA from the second quarter of 2026 to the second quarter of 2026 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics


What is Protagenic Therapeutics Inc New's ROA in the second quarter of 2026?
Protagenic Therapeutics Inc new achieved a return on average assets (ROA) of 103.96 % in its second quarter of 2026, this is above PTIX's average return on assets of -163.36%.
Protagenic Therapeutics Inc New assets over the 12 months ending in its second quarter of 2026 are valued at $5 million

ROA has improved compared to 89.64% in the first quarter of 2026, due to net income growth.

However, within the Healthcare sector 7 other companies had a higher return on assets. While return on assets, the total ranking has deteriorated compared to the first quarter of 2026 from 4676 to 5073.

What is ROA?



Return On Assets (Sep 30 2026)
II. Quarter
(Jun 30 2026)
I. Quarter
(Mar 31 2026)
IV. Quarter
(Dec 31 2025)
III. Quarter
(Sep 30 2025)
II. Quarter
Y / Y Total Assets Change -51.56 % -56.99 % 9227.31 % 126.55 % 231.68 %
Y / Y Net Income Change - - - - -
Net Income (TTM) in million 6 5 1 -5 -8
Return On Assets (TTM) 103.96 % 89.64 % 19.49 % -128.38 % -241.87 %
PTIX's Total Ranking # 5073 # 4676 # 4793 # 4826 # 5506
Total Assets (TTM) in million 2 3 12 4 5
Seq. Total Assets Change -13.33 % -76.97 % 174.04 % -11.43 % -23.04 %
Seq. Net Income Change - - 129.98 % - -



Return On Assets Company Ranking
Within: No.
Industry # 3
Sector # 8
Overall # 37

Return On Assets Statistics
High Average Low
137.58 %
-163.36 %
-454.01 %
(Jun 30 2026)   (Dec 31 2015)





Financial Statements
Protagenic Therapeutics Inc New's Assets $ 2 million PTIX's Balance sheet
Protagenic Therapeutics Inc New's Income $ -1 million Quarterly PTIX's Income Statement
PTIX's Income by Division See PTIX's Income by Division



Annual Return On Assets (Mar 31 2026)
FY 2026
(Dec 31 2024)
FY 2024
(Dec 31 2023)
FY 2023
(Dec 31 2022)
FY 2022
(Dec 31 2021)
FY 2021
Y / Y Total Assets Change 520.85 % -54.76 % -46.21 % -27.33 % 1157.82 %
Total Assets in million 12 2 4 8 11
Y / Y Net Income Change - - - - -
Net Income in million 1 -6 -5 -4 -5
Annual Return On Assets 11.27 % -282.49 % -115.66 % -44.24 % -40.89 %




Comment on PTIX's ROA in the fiscal year ending 2026
In the fiscal year 2026 ROA improved to 11.27 % compared to prior year, due to annual net income growth of % to $1.37 million, while value of Protagenic Therapeutics Inc New's overall assets grew just by 520.85 % to $12.14 million, compared to $12.14 a year before.


More Return On Assets Ratios
PTIX's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
PTIX's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for PTIX's Competitors
Subscribers only: Roa for Protagenic Therapeutics Inc New's Suppliers
Subscribers only: Return On Assets for PTIX's Customers

You may also want to know
PTIX's Roi PTIX's Inventory Turnover Ratio PTIX's Growth Rates PTIX's Dividend Comparisons
PTIX's Profitability Ratios PTIX's Asset Turnover Ratio PTIX's Dividend Growth
PTIX's Roe PTIX's Valuation Ratios PTIX's Financial Strength Ratios PTIX's Dividend Payout Ratio



Companies with similar Return On Assets at Sep 30 2026, within Healthcare Sector ROA
Vor Biopharma Inc   277.94 %
Exelixis Inc   63.88 %
Rigel Pharmaceuticals Inc  59.56 %
Alnylam Pharmaceuticals Inc   46.08 %
Ironwood Pharmaceuticals inc   42.53 %
Aurinia Pharmaceuticals Inc   40.63 %
Nurix Therapeutics Inc   38.61 %
Indivior Pharmaceuticals Inc   36.35 %
Rallybio Corporation  34.55 %
Idexx Laboratories Inc  34.05 %
Zevra Therapeutics Inc   26.33 %
Caredx Inc   25.74 %
Medpace Holdings Inc   24.47 %
Acadia Pharmaceuticals Inc   21.60 %
Standard Biotools Inc   21.56 %
Eli Lilly And Company  21.24 %
Iradimed Corporation  20.89 %


Date modified: 2026-11-07T06:41:04+00:00


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.